Cart
sales@molnova.com
Linvencorvir
CAS No. 1808248-05-6
Linvencorvir( —— )
Catalog No. M35768 CAS No. 1808248-05-6
Linvencorvir is a hepatitis B virus (HBV) core protein variant modifier used to treat chronic HBV infection.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 1034 | Get Quote |
|
| 5MG | 1112 | Get Quote |
|
| 10MG | 1805 | Get Quote |
|
| 25MG | 1995 | Get Quote |
|
| 50MG | 2190 | Get Quote |
|
| 100MG | 2790 | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameLinvencorvir
-
NoteResearch use only, not for human use.
-
Brief DescriptionLinvencorvir is a hepatitis B virus (HBV) core protein variant modifier used to treat chronic HBV infection.
-
DescriptionLinvencorvir is an antiviral agent.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayMicrobiology/Virology
-
TargetHBV
-
RecptorHBV | Antibiotic
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1808248-05-6
-
Formula Weight598.69
-
Molecular FormulaC29H35FN6O5S
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 62.5 mg/mL (104.39 mM; Ultrasonic (<60°C)
-
SMILESC(OCC)(=O)C=1[C@@H](NC(=NC1CN2C[C@@]3(N(CC2)C(=O)N(CC(C(O)=O)(C)C)C3)[H])C4=NC=CS4)C5=C(C)C(F)=CC=C5
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. International Nonproprietary Names for Pharmaceutical Substances (INN). WHO Drug Information, Vol. 35, No. 4, 2021
molnova catalog
related products
-
Lagociclovir
Lagociclovir (MIV-210), a nucleoside analogue, is an antiviral compound available for the treatment of HBV82 that inhibits the replication of wild-type hepatitis B virus (HBV) in human hepatocellular carcinoma cell lines that permanently express HBV.
-
Entecavir hydrate
Entecavir, a new deoxyguanine nucleoside analogue, is a selective inhibitor of the replication of the hepatitis B virus (HBV).
-
ccc_R08
ccc_R08 is an orally available HBV cccDNA inhibitor that reduces extracellular levels of HBV DNA, HBsAg, and HBeAg in a dose-dependent manner. ccc_R08 is investigational for use in the treatment of HBV infections. ccc_R08 has been shown to be effective in the treatment of hepatitis C virus (HCV).
